Do-Youn Oh

27PUBLICATIONS

256CO-AUTHORS

Molecular targetsPredictive and prognostic markersChemotherapyCancer therapy (excl. chemotherapy and radiation therapy)Cheminformatics and quantitative structure-activity relationships

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (27)

Sort by Publication Date:

|May 07, 2026

Promising New Platforms and Targets in the Management of Gastroesophageal Cancers.

|Apr 09, 2026

Post-Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors.

Vicky Makker, Jung-Yun Lee, Do-Youn Oh

|Mar 23, 2026

Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients with Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies.

Keun-Wook Lee, Elena Elimova, Do-Youn Oh

|Dec 29, 2025

MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the IFN Response.

Jinkai Wan, Hatice Duygu Saatcioglu, Haley Ellis

|Dec 01, 2025

Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma.

Keun-Wook Lee, Li-Yuan Bai, Minkyu Jung

|Nov 18, 2025

Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up.

Marcia Cruz-Correa, Do-Youn Oh, Ken Kato

Pageof 5

Frequent Collaborators

Funda Meric-Bernstam

Keun-Wook Lee

Josep Tabernero

Teresa Macarulla Mercade

Lipika Goyal

Mitesh J Borad

Eric Van Cutsem

Joon Oh Park

Jeesun Yoon

Vicky Makker

Frequent Collaborators

Funda Meric-Bernstam

Keun-Wook Lee

Josep Tabernero

Teresa Macarulla Mercade